XCUR17 / Exicure - LARVOL DELTA

"Ichthyosis Pipeline Insights 2019 - Key Players are Mayne Pharma/Galderma (Trifarotene), Patagonia Pharmaceuticals (PAT-001), Exicure (XCUR 17) - https://t.co/guyiBzPH8C https://t.co/KhVoNlpQqA" (@NewsFromBW)

Exicure presents positive biomarker results from clinical trial of XCUR17 (Businesswire) - "Exicure...presented clinical data from the company’s drug candidate XCUR17 in psoriasis today during the Oligonucleotides Clinical Studies session at the 15th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) in Munich....Clinical results presented show decrease in the levels of psoriasis and inflammation markers..."

P1 data

Exicure to present clinical results from XCUR17 at the 15th Annual Meeting of the Oligonucleotide Therapeutics Society (Businesswire) - "Exicure...announced today that its CEO, David Giljohann, PhD, will present clinical data from the company’s Phase 1 study of its drug candidate XCUR17 in psoriasis....Wednesday, October 16, 2019 at the 15th Annual Meeting of the Oligonucleotide Therapeutics Society in Munich."

P1 data